Management of refractory lupus nephritis: rationale to consider tacrolimus

Kidney Int. 2022 Jun;101(6):1293. doi: 10.1016/j.kint.2022.03.004.

Authors

Durga Prasanna Misra¹, Vikas Agarwal²

Affiliations

¹ Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Electronic address: durgapmisra@gmail.com.
² Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

PMID: 35597593
DOI: 10.1016/j.kint.2022.03.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immunosuppressive Agents / therapeutic use
Lupus Nephritis* / drug therapy
Mycophenolic Acid
Tacrolimus* / therapeutic use
Treatment Outcome

Substances

Immunosuppressive Agents
Mycophenolic Acid
Tacrolimus